rotigotine


Also found in: Wikipedia.

rotigotine

an antiparkinson agent.
indication This drug is used to treat idiopathic Parkinson's disease.
contraindications Defibrillation, MRI, and known hypersensitivity to this drug prohibit its use.
adverse effects Adverse effects of this drug include drowsiness, hallucinations, headache, malaise, paresthesia, vertigo, confusion, dizziness, dyskinesia, fatigue, fever, insomnia, sudden sleep onset, edema, hypertension, sinus tachycardia, orthostatic hypotension, dyspepsia, anorexia, constipation, vomiting, xerostomia, weight gain, urinary incontinence, dermatitis, erythema, rash, pruritus, purpura, arthralgia, and back pain. A life-threatening side effect is anaphylaxis. A common side effect is nausea.
References in periodicals archive ?
Food and Drug Administration (FDA) has approved the drugs gabapentin enacarbil (Horizant[R]), pramipexole (Mirapex[R]), ropinirole (Requip[R]), and rotigotine (Neupro[R]) to treat moderateto-severe RLS.
Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER).
Such formulations include those containing: Buprenorphine, Fentanyl, Methylphenidate, Rivastigmine, and Rotigotine.
In this regard, studies assessing the benefits of slow release formulations of ropinirole, rotigotine, or L-DOPA showed an improvement in the sleep quality of patients with PD [233-235].
These findings confirm and extend those of several previous reports in the literature, but none of the dopamine receptor agonists--pramipexole, ropinirole, cabergoline, bromocriptine, rotigotine, and apomorphine--currently carry a boxed warning about the potential for developing severe impulse control disorders.
M2 EQUITYBITES-August 26, 2014-Actavis submits abbreviated new drug application for Rotigotine Extended-release Transdermal Film
M2 PHARMA-August 26, 2014-Actavis submits abbreviated new drug application for Rotigotine Extended-release Transdermal Film
This rate of augmentation with use of rotigotine is significantly lower than other dopamine agonists.
Rotigotine is a non-ergot dopamine agonist that is suitable for transdermal delivery via skin patches, (5) once administered daily, it provides stable plasma concentrations over 24 hours.
We used non--ergot agonists such as: Pramipexole, Rotigotine and Ropinirole in our study.
This edition has new drugs, including aclidinium bromide, felbamate, icosapent ethyl, linaclotide, peginesatide acetate, perampanel, rotigotine, and teriflunomide, and updated group monographs for antipsychotic agents, benzodiazepenes, calcium channel blocking agents, estrogens, macrolides, opioid analgesics, proton pump inhibitors, selective serotonin reuptake inhibitors, and serotonin 5-HT1 receptor agonists.
The dopamine receptor agonist rotigotine significantly reduced symptoms of restless legs syndrome in a multicenter placebo-controlled trial.